Mouse anti-mouse mAbs
Recombinant monoclonal antibodies for in vivo use
InvivoGen offers an expanding collection of InvivoFit™ recombinant mouse anti-mouse monoclonal antibodies (mAbs). These mAbs were engineered to limit their immunogenicity for a constant efficacy upon repeated injections in mice. Our collection includes mAbs targeting immune checkpoints such as PD-1, and tumor-associated antigens such as gp75. These mAbs are produced in Chinese hamster ovary (CHO) cells and are provided in an InvivoFit™ grade, a high quality standard specifically adapted to in vivo studies.
Features of InvivoFit™ mouse anti-mouse mAbs:
- Sequence is 85% to 100% murine
- Guaranteed sterile, endotoxin level: <1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation: < 5%
InvivoGen's recombinant mouse anti-mouse mAbs include antibodies for which the sequence is either 100% mouse origin (constant and variable regions), or ~85% mouse origin (constant regions) and ~15% non-mouse origin (variable regions). The minimal use of xenogeneic sequences limits the immunogenicity of the mAb. Indeed, a major pitfall encountered in murine in vivo studies aimed at evaluating the activity of a mAb upon repeated injections, is the decrease and loss of antibody performance if its sequence is not of mouse origin. Repeated injections in mice lead to anti-species antibody generation by the host (e.g. anti-rat antibodies if the mAb was produced in rats). This occurrence increases as the fraction of non-mouse sequences increases. Replacing xenogeneic sequences with mouse sequences reduces antibodies immunogenicity, and thus helps retain their activity in vivo.